The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with unresectable malignant pleural mesothelioma (MPM).
 
Santiago Ponce
No Relationships to Disclose
 
Susana Cedres Perez
Consulting or Advisory Role - Amphera; Bristol-Myers Squibb; MSD Oncology
 
Charles Ricordel
Consulting or Advisory Role - AstraZeneca/MedImmune; BMS; Takeda; Takeda
 
Nicolas Isambert
Consulting or Advisory Role - Amgen; Daichii; Eisai; Ipsen; Pfizer; Transgene
Travel, Accommodations, Expenses - AstraZeneca; Novartis; PharmaMar; Roche/Genentech
 
Victor Levitsky
Employment - Molecular Partners; SERVIER; Targovax
Leadership - Targovax
Stock and Other Ownership Interests - Targovax
Consulting or Advisory Role - Athebio
Patents, Royalties, Other Intellectual Property - Molecular Partners; Targovax
 
Thomas Birkballe Hansen
No Relationships to Disclose
 
Magnus Erik Jaderberg
Employment - Targovax
Leadership - Targovax
Stock and Other Ownership Interests - Targovax
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Hutchmed (I); Ipsen; Lilly; Merck Serono; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)